Invokana (canagliflozin) — United Healthcare
diabetic nephropathy with albuminuria > 300 mg/day
Preferred products
- Jardiance (empagliflozin)
Initial criteria
- Diagnosis of type 2 diabetes mellitus
- Diagnosis of diabetic nephropathy with albuminuria > 300 mg/day
- Provider attests that Jardiance isn’t a suitable treatment option
- Submission of medical records (laboratory and clinical documentation) confirming diagnosis of kidney disease
Reauthorization criteria
- Documentation of a positive clinical response to Invokana therapy
Approval duration
12 months